Coherus Gets Goal Date On US Adalimumab Biosimilar

Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target

17 Feb 2021

A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.

Calendar 2021 — Coherus has received a goal date from the FDA • Source: Shutterstock

Coherus BioSciences expects to receive a US Food and Drug Administration decision on its CHS-1420 adalimumab biosimilar candidate in December this year, the firm has revealed, after the agency accepted for filing its biologics license application for the rival to Humira.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J Denied Injunction Over Private-Label Ustekinumab In US

01 May 2025

• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

01 May 2025

• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.